Increasing awareness of health care disparities has prompted reexamination of the National Quality Forum recommendation that measures of health care quality not be adjusted for patients' sociodemographic characteristics. Adjustment might appear to endorse poorer-quality care for those traditionally underserved. However, Fiscella and colleagues 1 pointed out that failure to adjust for sociodemographic differences might unfairly penalize health systems serving disadvantaged groups. Jha and Zaslavsky 2 argued that quality measures should be adjusted for patient characteristics when differences between health systems are confounded by differences between the patients they serve. In those cases, stratified reporting of quality measures would both reveal health disparities and permit fairer comparisons of quality across health systems or facilities. Given that rates of mental health treatment differ markedly by race and ethnicity, 3 this cohort study examined how stratifying by race/ethnicity would affect a specific mental health care quality measure: the proportion of outpatients starting antidepressant treatment who receive adequate or potentially effective acute-phase treatment. 4 Methods | The participating health systems (Group Health Cooperative, HealthPartners, Kaiser Permanente Colorado, Kaiser Permanente Hawaii, and Kaiser Permanente Southern California) serve more than 6 million patients, with each system's membership representing the racial/ethnic distribution of its service area ( Table 1 ). Using methods previously described, 5 health system records identified adult outpatients beginning a new episode of antidepressant treatment for a depressive disorder between January 1, 2010, and December 31, 2012. Selfreported race/ethnicity was identified from electronic medical records. Pharmacy dispensing records were used to identify patients receiving more than 90 days' supply of any antidepressant medication over 180 days, beginning with the index prescription, similar to the National Committee for Quality Assurance/Healthcare Effectiveness Data and Information Set measure of adequate acute-phase treatment. 4 The sample was limited to patients continuously enrolled from 270 days before to 180 days after the index prescription. The health systems' institutional review boards granted waivers of consent for use of deidentified data. Results | The overall proportion of patients meeting this threshold for effective acute-phase treatment varied from 58.2% to 69.9% across the 5 health systems ( Table 2) . This proportion varied markedly across racial/ethnic groups but showed a similar pattern across health systems (highest in non-Hispanic white individuals, lower in Asian and Hispanic individuals, and lowest in African American individuals). Rates for Native Hawaiian and Pacific Islander individuals were the most variable across sites. When rates for each health system were standardized to replicate the race/ethnicity distribution of the entire sample, 6 overall rates of adequate treatment varied from 60.5% to 65.6%.
Discussion | Most of the observed variation across health systems in overall rates of effective acute-phase antidepressant treatment reflected differences in the racial/ethnic distribution of patient populations. Standardizing across health systems reduced the range in performance from approximately 12% to approximately 5% and significantly altered the overall ranking of these health systems. Rankings also varied widely across racial/ethnic groups, with every health system ranking first or second in at least 1 group. We could not determine whether lower rates of adequate treatment in some racial or ethnic groups reflect disparities in clinical practice (which should be reduced) or differences in patients' informed treatment preferences (which should be respected). In either case, use of unadjusted overall rates would bias comparisons between health systems. Unadjusted comparisons could create perverse incentives, punishing a health system for identifying and treating depression in traditionally underserved groups. Stratified rates also revealed important opportunities for improving care in traditionally underserved groups.
In these 5 health systems, most of the variation in overall rates of adequate acute-phase antidepressant treatment was owing to confounding by racial/ethnic differences in the patients they serve. Consistent with recommendations of Fiscella et al 1 and Jha and Zaslavsky, 2 comparison of depression care across health systems-and incentives to improve health system performance-should be based on stratified performance measures.
COMMENT & RESPONSE The Classification of Biomarkers
To the Editor In JAMA Psychiatry, Pine and Leibenluft 1 highlighted the importance of biomarkers in elucidating mechanisms. However, there is an issue regarding the nomenclature of biomarkers that clouds the field in that the term biomarker is typically used as an interchangeable umbrella term for a diversity of biological and clinical phenomena. The fields would be assisted in this regard by greater systematized precision in the use of the term biomarker. Specifically, adoption of an agreed classification might aid clarity. As an example, Davis and colleagues 2 defined 6 categories of biomarkers, namely: (1) biomarkers of risk predict whether an individual is predisposed to developing any disorder; (2) diagnostic or trait biomarkers are measurable characteristics reflecting the presence of a disease state; (3) state or acuity biomarkers are a measurable characteristic reflecting the severity of a disease process; (4) stage biomarkers reflect extant staging classifications allowing categorization of an individual's present illness stage; (5) response biomarkers index the probability of response to a given treatment; and (6) prognostic biomarkers predict the likely outcome and course of an illness. Weickert and colleagues 3 similarly classified biomarkers into diagnostic, prognostic, and theranostic. 
